Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBluecross Idaho Yartemlea Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedBluecross IdahoPolicy MP 5.01.677

    Yartemlea (narsoplimab-wuug) for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy MP 5.01.677 alerts

    Get alerted when Policy MP 5.01.677 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity and prior-authorization requirements for intravenous Yartemlea in adults and children at least 2 years old with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). It specifies diagnostic confirmation, documentation, specialist involvement, dosing, quantity limits, and continuation-response requirements.

    Policy Summary
    PayerBluecross Idaho
    PolicyYartemlea (narsoplimab-wuug) for TA-TMA
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateSep 1, 2026
    Last ReviewMay 28, 2026
    Next Review DateN/A
    Key ActionSubmit prior-authorization documentation confirming patient age, post-HSCT TA-TMA, accepted diagnostic confirmation, specialist involvement, and a request within the 24-vial limit for 12 weeks.
    SourceLink
    POLICY UPDATE CHANGES

    Blue Cross of Idaho added a new policy addressing intravenous Yartemlea (narsoplimab-wuug) for hematopoietic stem cell transplant-associated thrombotic microangiopathy.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥2 yearsMinimum patient age
    24 vialsInitial authorization limit
    24 vialsContinuation authorization limit
    61%TMA response in study
    Serious infectionsSafety warning

    Coverage Criteria

    Initial Therapy Criteria

    Yartemlea may be considered medically necessary when all of the following are met.

    Initial therapy

    • Patient and diagnosis: The patient is 2 years of age or older, has documented hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), and is post-hematopoietic stem cell transplant (HSCT).age ≥2 years
    • Diagnostic confirmation

      • Biopsy confirmation: Histological evidence of microangiopathy is present on biopsy of an affected organ, such as the kidney or intestines.
      • Clinical diagnostic features

        • Anemia: Failure to achieve transfusion independence, hemoglobin decline from baseline by at least 1 g/dL, or new onset of transfusion dependence.hemoglobin decline ≥1 g/dL from baseline
        • Thrombocytopenia: Higher-than-expected platelet transfusion needs, refractoriness to platelet transfusions, a 50% or greater reduction in baseline platelet count after full platelet engraftment, or platelet count less than 150,000/μL.platelet reduction ≥50% or platelet count <150,000/μL
        • Elevated LDH: Elevated lactate dehydrogenase (LDH).
        • Schistocytes: Presence of schistocytes.
        • Hypertension: Presence of hypertension.
        • Elevated sC5b-9: Elevated soluble complement 5b-9 (sC5b-9).
        • Renal dysfunction, such as proteinuria defined as a random urine protein-to-creatinine ratio of at least 1 mg/mg.rUPCR ≥1 mg/mg
    • Additional requirements: Alternative diagnoses, such as autoimmune or alloimmune hemolytic anemia, thrombotic thrombocytopenic purpura, and Shiga toxin-producing Escherichia coli-induced hemolytic uremic syndrome, have been ruled out; TA-TMA triggers, including calcineurin inhibitor toxicity, graft-versus-host disease, and infections, have been evaluated and are being appropriately managed; and the prescriber is a specialist in the area of the patient's diagnosis or has consulted with one.
    • Dosing: The requested dose and frequency follow the specified weight-based regimen for TA-TMA: patients weighing less than 50 kg receive 4 mg/kg intravenously once weekly, and patients weighing 50 kg or more receive 370 mg intravenously once weekly.

      Frequency may be increased to twice weekly if there is inadequate improvement in TA-TMA signs and symptoms.

    • Quantity limit: The requested quantity does not exceed the maximum allowed for the approval duration.maximum 24 vials for 12 weeks

    Continuation Therapy Criteria

    Continuation requests may be considered medically necessary when all of the following are met.

    Continuation therapy

    • Prior initiation eligibility: Coverage criteria for initiation of Yartemlea were previously met, or the patient would have met the initial approval criteria when therapy started.
    • Positive clinical response

      • TMA laboratory response: Improvement in thrombotic microangiopathy laboratory markers, such as improvement in platelet counts, reduction in lactate dehydrogenase (LDH) and soluble complement 5b-9 (sC5b-9), or resolution of schistocytes.
      • Organ-function response: Improvement in organ function, such as reduction in proteinuria, reduction in transfusion requirements, improvement in blood pressure control, or resolution of gastrointestinal manifestations.

    Coding and Clinical Parameters

    CPTCPT
    C9399Unclassified drugs or biologicals
    HCPCSHCPCS
    J3490Unclassified drugs
    J3590Unclassified biologics
    J1289Injection, narsoplimab-wuug, 1 mg; effective July 1, 2026
    ICD-10-CMICD-10
    M31.11Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA)
    ICD-10-PCSICD-10
    XW03357Introduction of narsoplimab monoclonal antibody into a peripheral vein
    XW04357Introduction of narsoplimab monoclonal antibody into a central vein
    Place of Servicemixed
    OutpatientPlace of service: Outpatient
    InpatientPlace of service: Inpatient
    Minimum Age
    Minimum eligible age2 years of age or older
    Applies toAdults and pediatric patients
    Covered treatmentYartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)
    Platelet Diagnostic Feature
    Platelet thresholdPlatelet count less than 150,000/μL
    Diagnostic featureThrombocytopenia

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for initial Yartemlea treatment. Approval may be considered only when all initial-treatment criteria are met, including age, confirmed post-HSCT TA-TMA, specialist involvement, management of triggers and alternative diagnoses, and compliance with dosing limits.

    • Patient is 2 years of age or older.
    • Diagnosis of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) is documented, and the patient is post-hematopoietic stem cell transplant (HSCT).
    • TA-TMA is confirmed by either histological evidence of microangiopathy on biopsy or at least four specified diagnostic features.
    • Alternative diagnoses have been ruled out, and TA-TMA triggers such as calcineurin inhibitor toxicity, graft-versus-host disease, and infections have been evaluated and appropriately managed.
    • The prescriber is a specialist in the patient's diagnosis or has consulted with one.
    • The requested quantity does not exceed the maximum allowed for the approval duration: 24 vials per 12 weeks.

    Therapy Background

    Yartemlea (narsoplimab-wuug) is a humanized monoclonal antibody and the first FDA-approved intravenous MASP-2 inhibitor for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adults and children 2 years and older. It targets mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin complement pathway. In TA-TMA, MASP-2 inhibition is intended to reduce lectin-pathway-mediated cellular injury, including endothelial injury in small blood vessels, by selectively blocking lectin-dependent activation of complement components C3 and C4 while leaving the classical and alternative complement pathways unaffected.

    Definitions

    Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA)
    ConditionA thrombotic microangiopathy associated with hematopoietic stem cell transplantation
    Underlying injuryMicrovascular injury, including endothelial cell injury in small blood vessels
    Associated findingsRelated laboratory and organ-function abnormalities
    MASP-2
    Full nameMannan-binding lectin-associated serine protease-2
    RoleEffector enzyme of the lectin pathway of complement
    Yartemlea target

    Yartemlea Initial Therapy

    Yartemlea Initial Therapy

    Initial therapy may be considered medically necessary when the patient meets all of the following requirements.

    Yartemlea initial therapy

    • Patient and post-transplant diagnosis: The patient is 2 years of age or older, has documented hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), and is post-hematopoietic stem cell transplant (HSCT).age ≥2 years
    • Diagnostic confirmation

      • Biopsy confirmation: Histological evidence of microangiopathy is present on biopsy of an affected organ, such as the kidney or intestines.
      • Clinical diagnostic features

    Yartemlea Continuation

    Yartemlea Continuation

    Continuation requests may be considered medically necessary when all of the following requirements are met.

    Yartemlea continuation

    • Prior initiation eligibility: Coverage criteria for initiation were previously met, or the patient would have met the initial approval criteria when therapy started.
    • Documented positive response

      • TMA laboratory markers: There is improvement in TMA laboratory markers, such as improved platelet counts, reduced LDH and sC5b-9, or resolution of schistocytes.
      • Organ function: There is improvement in organ function, such as reduced proteinuria, reduced transfusion requirements, improved blood pressure control, or resolution of gastrointestinal manifestations.

    Quantity Limits

    Yartemlea (narsoplimab-wuug) — Initial Authorization
    Treatment phaseInitial authorization
    Quantity limit24 vials
    Approval duration12 weeks
    Yartemlea (narsoplimab-wuug) — Continuation Authorization
    Treatment phaseContinuation authorization
    Quantity limit24 vials
    Approval duration12 weeks

    Administration Site

    Note

    Intravenous administration; site not specified

    Yartemlea is administered intravenously. The policy does not specify a required administration site, so it does not limit administration to a particular site of care.

    • Administration is IV.
    • No required administration site is specified in the policy.
    Policy Summary
    PayerBluecross Idaho
    PolicyYartemlea (narsoplimab-wuug) for TA-TMA
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateSep 1, 2026
    Last ReviewMay 28, 2026
    Next Review DateN/A
    Key ActionSubmit prior-authorization documentation confirming patient age, post-HSCT TA-TMA, accepted diagnostic confirmation, specialist involvement, and a request within the 24-vial limit for 12 weeks.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ParametersAuthorization and Documentation RequirementsTherapy BackgroundDefinitionsYartemlea Initial TherapyYartemlea ContinuationQuantity LimitsAdministration Site
    Safety: The patient has not experienced unacceptable toxicity or adverse events requiring discontinuation of Yartemlea.
  1. Specialist involvement: The prescriber is a specialist in the area of the patient's diagnosis, such as a hematologist, or has consulted with a specialist in that area.
  2. Quantity limit: The requested quantity does not exceed the maximum vials allowed for the duration of approval.maximum 24 vials for 12 weeks
  3. Additional platelet findingA 50% reduction or greater in baseline platelet count after full platelet engraftment may also support the diagnosis
    Renal Diagnostic Feature
    Renal thresholdRandom urine protein-to-creatinine ratio (rUPCR) ≥ 1 mg/mg
    Diagnostic featureRenal dysfunction
    Finding describedProteinuria
    Diagnostic Feature Count
    Required numberAt least 4 diagnostic features
    Alternative confirmationTA-TMA may also be confirmed by histological evidence of microangiopathy on biopsy of an affected organ
    Listed featuresAnemia, thrombocytopenia, elevated LDH, schistocytes, hypertension, elevated sC5b-9, or renal dysfunction
    Treatment Quantity Limit
    Quantity limit24 vials
    Approval duration12 weeks
    Applies toInitial and continuation treatment
    Prior Authorization

    Continuation Authorization Required

    Continuation authorization is required for ongoing Yartemlea treatment. Continuation may be approved when initiation criteria were previously met, or would have been met when therapy began, and the patient has documented clinically meaningful response without unacceptable toxicity.

    • Prior initiation criteria were met, or the patient would have met those criteria when therapy started.
    • Documented positive clinical response includes both improvement in TMA laboratory markers and improvement in organ function.
    • No unacceptable toxicity or adverse event requiring discontinuation has occurred.
    • The prescriber is a specialist in the patient's diagnosis or has consulted with one.
    • The requested quantity does not exceed 24 vials per 12 weeks.
    Documentation Required

    Initial-Treatment Documentation

    Submit documentation supporting every initial-treatment criterion with the prior-authorization request. The record must establish the diagnosis, transplant status, confirmation of TA-TMA, appropriate clinical management, specialist participation, and requested quantity.

    • Patient age and documentation of post-HSCT status.
    • Diagnosis of TA-TMA.
    • Confirmation by biopsy showing microangiopathy or at least four diagnostic features: anemia, thrombocytopenia, elevated LDH, schistocytes, hypertension, elevated sC5b-9, or renal dysfunction/proteinuria.
    • Documentation that alternative diagnoses have been ruled out.
    • Documentation that potential TA-TMA triggers have been evaluated and are being appropriately managed.
    • Prescriber specialty or specialist consultation documentation.
    • Requested dose, frequency, treatment duration, and total quantity, including confirmation that the request is within the 24-vial/12-week limit.
    Documentation Required

    Continuation Documentation

    Continuation requests must document that the patient remains an appropriate candidate and is benefiting from Yartemlea. Submit objective response data and safety information with each request.

    • Evidence that initial criteria were previously met or that the patient would have met them when therapy began.
    • Improvement in TMA laboratory markers, such as platelet count, LDH, sC5b-9, or schistocytes.
    • Improvement in organ function, such as proteinuria, transfusion requirements, blood-pressure control, or gastrointestinal manifestations.
    • Documentation that no unacceptable toxicity or adverse event requires discontinuation.
    • Prescriber specialty or specialist consultation documentation.
    • Requested dose, frequency, treatment duration, and total quantity, including confirmation that the request is within the 24-vial/12-week limit.
    Note

    Dosing and Infection-Safety Documentation

    Document the prescribed regimen and quantity, and monitor for infection throughout treatment. Patients with active infections require close monitoring for worsening infection and prompt treatment if infection develops or worsens.

    • For patients weighing 50 kg: 4 mg/kg IV once weekly.
    • For patients weighing ≥ 50 kg: 370 mg IV once weekly.
    • Increase frequency to twice weekly only when there is inadequate improvement in TA-TMA signs and symptoms.
    • Initial-treatment limit: 24 vials for 12 weeks.
    • Continuation-treatment limit: 24 vials for 12 weeks.
    • Yartemlea carries warnings for serious infections, including sepsis, viral infections, pneumonia, bacteremia, fungal infection, gastroenteritis, respiratory tract infections, and urosepsis.
    • If administered during an active infection, monitor closely for worsening infection and treat promptly.
    Denial Risk

    When Initial Criteria Are Not Met

    The initial request should be denied or returned for correction when the patient does not meet the initial-treatment requirements or the submitted record does not substantiate them.

    • Patient is younger than 2 years.
    • TA-TMA, post-HSCT status, or required diagnostic confirmation is not documented.
    • Fewer than four required diagnostic features are documented when biopsy confirmation is unavailable.
    • An alternative diagnosis has not been ruled out.
    • TA-TMA triggers have not been evaluated or appropriately managed.
    • The prescriber is neither a qualified specialist nor supported by specialist consultation.
    • The requested quantity exceeds 24 vials for 12 weeks or otherwise exceeds the maximum allowed for the approval duration.
    Denial Risk

    When Continuation Criteria Are Not Met

    The continuation request should be denied or not renewed when the patient does not meet continuation requirements or the record does not demonstrate ongoing benefit and tolerability.

    • Initial-treatment criteria were not previously met and the patient would not have met them when therapy began.
    • No documented positive clinical response in both TMA laboratory markers and organ function.
    • Unacceptable toxicity or an adverse event requires discontinuation.
    • The prescriber is neither a qualified specialist nor supported by specialist consultation.
    • The requested quantity exceeds 24 vials for 12 weeks or otherwise exceeds the maximum allowed for the approval duration.
    Narsoplimab inhibits MASP-2
    TMA Response
    Laboratory responseImprovement in TMA laboratory markers, including improved platelet counts and reduced LDH and sC5b-9 or resolution of schistocytes
    Organ-function responseImprovement in organ function, such as reduced proteinuria, reduced transfusion requirements, improved blood pressure control, or resolution of gastrointestinal manifestations
    Continuation requirementBoth laboratory-marker improvement and organ-function improvement are required
  4. Anemia: Failure to achieve transfusion independence, hemoglobin decline from baseline by at least 1 g/dL, or new onset of transfusion dependence.hemoglobin decline ≥1 g/dL from baseline
  5. Thrombocytopenia: Higher-than-expected platelet transfusion needs, refractoriness to platelet transfusions, a 50% or greater reduction in baseline platelet count after full platelet engraftment, or platelet count less than 150,000/μL.platelet reduction ≥50% or platelet count <150,000/μL
  6. Elevated LDH: Elevated lactate dehydrogenase (LDH).
  7. Schistocytes: Presence of schistocytes.
  8. Hypertension: Presence of hypertension.
  9. Elevated sC5b-9: Elevated soluble complement 5b-9 (sC5b-9).
  10. Renal dysfunction, such as proteinuria defined as a random urine protein-to-creatinine ratio of at least 1 mg/mg.rUPCR ≥1 mg/mg
  11. Diagnosis and specialist management: Alternative diagnoses have been ruled out; TA-TMA triggers, including calcineurin inhibitor toxicity, graft-versus-host disease, and infections, have been evaluated and are being appropriately managed; and the prescriber is a relevant specialist or has consulted one.
  12. Dosing: For patients weighing less than 50 kg, the dose is 4 mg/kg intravenously once weekly. For patients weighing 50 kg or more, the dose is 370 mg intravenously once weekly.

    Increase frequency to twice weekly if there is inadequate improvement in TA-TMA signs and symptoms.

  13. Quantity: The requested quantity does not exceed the maximum vials allowed for the approval duration.maximum 24 vials for 12 weeks
  14. Safety and discontinuation: The patient has not experienced unacceptable toxicity or adverse events requiring discontinuation from Yartemlea.
  15. Specialist involvement: The prescriber is a specialist in the area of the patient's diagnosis, such as a hematologist, or has consulted with a specialist in that area.
  16. Authorization quantity: The requested quantity does not exceed the maximum vials allowed for the duration of approval.maximum 24 vials for 12 weeks